SCHEMBL21807293

SCHEMBL21807293

CC(=O)Oc1ccccc1C(F)F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 10/20 0.53
KDM4E B2RXH2 3/20 0.53
HSD17B10 Q99714 3/20 0.53
HPGD P15428 2/20 0.53
ALDH1A1 P00352 1/20 0.53
ESR1 P03372 1/20 0.53
ITGB3 P05106 1/20 0.53
ITGA2B P08514 1/20 0.53
HMGB1 P09429 1/20 0.53
TSHR P16473 1/20 0.53
GGT1 P19440 1/20 0.53
PTGS1 P23219 1/20 0.53
BLM P54132 1/20 0.53
NAPRT Q6XQN6 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
MAPK1 P28482 1/20 0.44
ACHE P22303 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL667361 0.84 KDM4E (0.40) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL11606741 0.83 PTGS2 (0.57) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL18499347 0.82 PTGS2 (0.55) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL720572 0.82 KDM4E (0.55) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL29432883 0.80 PTGS2 (0.68) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL338196 0.80 PTGS2 (0.68) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL8324534 0.80 PTGS2 (0.53) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL10812159 0.80 PTGS2 (0.53) PTGS2KDM4EHSD17B10HPGDALDH1A1
Hydrogen Peroxide SCHEMBL8008634 0.80 KDM4E (0.58) PTGS2KDM4EHSD17B10HPGDALDH1A1
SCHEMBL17355745 0.79 KDM4E (0.43) PTGS2KDM4EHSD17B10HPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4414365-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2024-08-14 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
EP-3852533-B1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO INC (US) 2024-02-28 EP disclosed
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-05-19 US disclosed
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. 2022-01-27 US disclosed
EP-3941475-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2022-01-26 EP disclosed
EP-3852533-A1 PYRIDAZINONES AND METHODS OF USE THEREOF Goldfinch Bio, Inc. (US) 2021-07-28 EP disclosed
US-11046690-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2021-06-29 US disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
WO-2020191056-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-09-24 WO disclosed
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-09-10 US disclosed
US-10654850-B2 Pyridazinones and methods of use thereof GOLDFINCH BIO, INC. (US) 2020-05-19 US disclosed
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-04-02 US disclosed
WO-2020061162-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2020-03-26 WO disclosed
CN-109415321-A aromatic sulfonamide derivatives 拜耳制药股份公司 2019-03-01 CN disclosed
CN-107848974-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2018-03-27 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024917-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN PTGS2 586/4885KDM4E 3398/4885HSD17B10 987/4885
US-20220152031-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GLS, ATP6V1B1, PDXK PTGS2 612/4885KDM4E 3965/4885HSD17B10 1123/4885
US-20200102301-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN PTGS2 586/4885KDM4E 3398/4885HSD17B10 987/4885
US-11046690-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN PTGS2 586/4885KDM4E 3398/4885HSD17B10 987/4885
US-20200283437-A1 PYRIDAZINONES AND METHODS OF USE THEREOF ATP6V1B1, GLS, REN PTGS2 586/4885KDM4E 3398/4885HSD17B10 987/4885
US-10654850-B2 Pyridazinones and methods of use thereof ATP6V1B1, GLS, REN PTGS2 586/4885KDM4E 3398/4885HSD17B10 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.